Overview

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

Status:
Recruiting

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dapagliflozin